56
psoralen/ultraviolet A and immunosuppression of organ transplant recipients. Photodermatol Photoimmunol Photomed 2004; 20: 289-96. 81) Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252-8. 82) Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol 2010; 49: 978-86. 83) Trautinger F. Phototherapy of mycosis fungoides. Photodermatol Photoimmunol Photomed 2011; 27: 68-74. 84) Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 2000; 136: 748-52. 85) Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976; 38: 683-9. 86) Roenigk HH Jr. Photochemotherapy for mycosis fungoides. Arch Dermatol 1977; 113: 1047-51. 87) Weischer M, Blum A, Eberhard F, Röcken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84: 370-4. 88) Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159: 931-5. 89) Smoller BR, Marcus R. Risk of secondary cutaneous malignancies in patients with long-standing mycosis fungoides. J Am Acad Dermatol 1994; 30: 201-4. 90) Stern RS; PUVA follow-up study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66: 553-62. 91) Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-5. 92) Stern RS, Liebman EJ, Vkev L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Followup Study. J Natl Cancer Inst 1998; 90: 1278-84. 93) Katz KA, Marcil I, Stern RS. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients. J Invest Dermatol 2002; 118: 1038-43.



65. SAYFAYA BENZER SAYFALAR

Puva ve dar bant uvb fototerapilerinin derideki etkilerinin dermoskopla izlenmesi - Sayfa 106
81. Murase JE, Lee EE, Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy Int J Dermatol 2005;44:1016-21. 82. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Eng J Med 1997;366:1041-5. 83. Akay BN. Bazal Hücreli...

65. SAYFADAKI ANAHTAR KELIMELER

dermatol
study
psoralen
oral
puva
therapy


65. SAYFA ICERIGI

56
psoralen/ultraviolet A and immunosuppression of organ transplant recipients. Photodermatol Photoimmunol Photomed 2004; 20: 289-96. 81) Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252-8. 82) Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol 2010; 49: 978-86. 83) Trautinger F. Phototherapy of mycosis fungoides. Photodermatol Photoimmunol Photomed 2011; 27: 68-74. 84) Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 2000; 136: 748-52. 85) Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976; 38: 683-9. 86) Roenigk HH Jr. Photochemotherapy for mycosis fungoides. Arch Dermatol 1977; 113: 1047-51. 87) Weischer M, Blum A, Eberhard F, Röcken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84: 370-4. 88) Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159: 931-5. 89) Smoller BR, Marcus R. Risk of secondary cutaneous malignancies in patients with long-standing mycosis fungoides. J Am Acad Dermatol 1994; 30: 201-4. 90) Stern RS; PUVA follow-up study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66: 553-62. 91) Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-5. 92) Stern RS, Liebman EJ, Vkev L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Followup Study. J Natl Cancer Inst 1998; 90: 1278-84. 93) Katz KA, Marcil I, Stern RS. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients. J Invest Dermatol 2002; 118: 1038-43.

İlgili Kaynaklar

single.php